ProtoKinetix

ProtoKinetix Liabilities

Delisted·Jul 27, 2026

The The Liabilities of ProtoKinetix (PKTX) as of Nov 18, 2026 is 185,434.00 USD. In the previous year, The Liabilities was 124,047.00 USD — a change of 49.49% (higher).

Liabilities

185,434.00USD

YoY

49.49%

Last updated:

In 2025, ProtoKinetix's total liabilities amounted to 185,434.00 USD, a 49.49% difference from the 124,047.00 USD total liabilities in the previous year.

The ProtoKinetix Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
78,885.00 USD
Jan 1, 2019
25,520.00 USD
Jan 1, 2020
44,960.00 USD
Jan 1, 2021
93,268.00 USD
Jan 1, 2022
41,530.00 USD
Jan 1, 2023
44,696.00 USD
Jan 1, 2024
124,047.00 USD
Jan 1, 2025
185,434.00 USD
The ProtoKinetix Liabilities history
YEARLiabilitiesYoY
185,434.00USD+49.49%
124,047.00USD+177.53%
44,696.00USD+7.62%
41,530.00USD-55.47%
93,268.00USD+107.45%
44,960.00USD+76.18%
25,520.00USD-67.65%
78,885.00USD-45.43%
144,562.00USD+219.16%
45,295.00USD-0.20%
45,388.00USD-89.55%
434,143.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ProtoKinetix Stock analysis

What does ProtoKinetix do? ProtoKinetix Inc. is a Canadian biotechnology company focused on the development of glycoproteins for therapeutic applications. The company was founded in 2005 and is headquartered in Marietta, USA. ProtoKinetix specializes in the research and development of AAGP® (Anti-Aging Glycopeptide) as biopharmaceuticals. These proprietary glycoproteins have the ability to protect cells and can be used in various therapeutic applications for improving damage in physical injury, spinal cord injury, diabetes, transplantation, and retinal diseases. In addition to the medical field, ProtoKinetix is also developing its patented technology for use in bio-agriculture and animal healthcare. It has a subsidiary that holds the rights to use and distribute AAGP® and its patents. ProtoKinetix's business model involves licensing its glycoprotein technology for various applications, including biopharmaceuticals, bioprocessing industries, and cell protection management for regenerative medicine and stem cell preparations. The company has established partnerships with other biotech companies to integrate its AAGP® technology into their product pipelines. ProtoKinetix's flagship product is the AAGP® protein solution, which is used as a medication in regenerative medicine, organ transplantation, eye healing, and animal health. It is also interested in researching the application of AAGP® in crop farming to increase yields and improve soil quality. ProtoKinetix is poised to play a significant role in the development of glycoproteins as future medicines and therapeutic technologies in various industries. It not only has the potential to explore healing medical products but also aims to enhance agriculture and animal care. ProtoKinetix represents an excellent example of a biotechnology company focused on improving the healthcare and agricultural industries. ProtoKinetix is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing ProtoKinetix's Liabilities

ProtoKinetix's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating ProtoKinetix's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing ProtoKinetix's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

ProtoKinetix's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in ProtoKinetix’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about ProtoKinetix stock

The Liabilities of ProtoKinetix is 185,434.00 USD in 2025.

The Liabilities of ProtoKinetix changed from 124,047.00 USD to 185,434.00 USD, representing a 49.49% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities ProtoKinetix since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's ProtoKinetix historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — ProtoKinetix

All Key Metrics — ProtoKinetix